All In Biotech

Drug Trial Radar · NCT05043922

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

93

Actual

Start

Oct 11, 2021

Primary completion

Jul 31, 2024

Study completion Feb 28, 2026

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.

Conditions

  • Ovarian Cancer
  • Recurrent Cancer

Interventions

  • CYH33Drug

    a Selective PI3Kα Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor ORR in patients with PIK3CA hotspot mutations.Time frame: through study completion, an average of 1 year

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, China

  • Chinese PLA General Hospital

    Beijing, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The Southwest Hospital of AMU

    Chongqing, China

  • Sun Yat-sen University Cancer Center

    Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangdong, China

  • The First Affiliated Hospital of Hainan Medical College

    Haikou, China

  • The Third People's Hospital of Hainan Province

    Hainan, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Hubei Cancer Hospital

    Hubei, China

  • Hunan Cancer Hospital

    Hunan, China

  • Qilu Hospital of Shandong University

    Jinan, China

  • Jiangsu Province Hospital

    Nanjing, China

  • The People's Hospital Of Guangxi Zhuang Autonomous Region

    Nanning, China

  • Qingdao Central Hospital

    Qingdao, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China

  • Shanghai First Maternity and Infant Hospital

    Shanghai, China

  • Xiaohua wu

    Shanghai, China

  • West China Second University Hospital, Sichuan University

    Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Zhejiang, China

  • Shikoku Cancer Center

    Matsuyama, Japan

  • Nagoya University Hospital

    Nagoya, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Hokkaido University Hospital

    Sapporo, Japan

  • Tohoku University Hospital

    Sendai, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • Jikei University Hospital

    Minato-Ku, Tokyo, Japan

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.